ABBV
NVS
New face, same pharma chessboard
Novartis just brought in Patrick Horber, an AbbVie veteran, to join its executive committee as President, International. That’s the role that helps steer how the company sells and expands its drugs outside the U.S., which is basically the global-growth engine room.
Why you should care
Marie-France Tschudin stepped down from the Chief Commercial Officer role, so this is not just a calendar update. Leadership changes in pharma can ripple into sales strategy, launch execution, and how aggressively a company goes after key international markets.
The AbbVie-to-Novartis move
Horber comes over from AbbVie, where he’s been Senior Vice President and President, Immunology. In other words: Novartis isn’t hiring a random middle manager here — it’s poaching someone with real big-pharma commercial muscle.
Big picture
This looks like a clean leadership handoff rather than a drama-filled shake-up. Still, when a company like Novartis reshuffles its global commercial bench, investors should keep an eye on whether the next chapter means smoother execution — or a fresh strategy playbook.